{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:58:45Z","timestamp":1793134725157,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ijantimicag.2020.106069","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T11:24:01Z","timestamp":1593257041000},"page":"106069","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review"],"prefix":"10.1016","volume":"56","author":[{"given":"Geren","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s F.","family":"Henao-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Franco-Paredes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4018-0195","authenticated-orcid":false,"given":"Daniel B.","family":"Chastain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.106069_bib0001","unstructured":"Dalvance (dalbavancin) [package insert]. Allergan USA: Madison, NJ;2018."},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0002","unstructured":"Orbactiv (oritavancin) [package insert]. The Medicines Company: Parsippany, NJ;2018."},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0003","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0004","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1128\/AAC.00981-15","article-title":"Oritavancin pharmacokinetics and bone penetration in rabbits","volume":"59","author":"Lehoux","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0005","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10096-016-2845-z","article-title":"Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE)","volume":"36","author":"Knafl","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0006","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1128\/AAC.00766-08","article-title":"Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro","volume":"53","author":"Belley","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0007","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1128\/AAC.00952-09","article-title":"Comparative in vitro activity profile of oritavancin against recent Gram-positive clinical isolates","volume":"53","author":"Arhin","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0008","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.diagmicrobio.2005.03.004","article-title":"Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens","volume":"53","author":"Streit","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0009","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.ajem.2016.04.022","article-title":"Intravenous home infusion therapy instituted from a 24-hour clinical decision unit for patients with cellulitis","volume":"34","author":"Rentala","year":"2016","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0010","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/j.1742-1241.2008.01824.x","article-title":"Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry","volume":"62","author":"Martone","year":"2008","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0011","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/bmj.38309.447975.EB","article-title":"Randomised controlled trial of intravenous antibiotic treatment for cellulitis at home compared with hospital","volume":"330","author":"Corwin","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0012","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1086\/313755","article-title":"Financial impact of a home intravenous antibiotic program on a medicare managed care program","volume":"30","author":"Dalovisio","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0013","first-page":"203","article-title":"Feasibility of outpatient self-administration of parenteral antibiotics","volume":"128","author":"Antoniskis","year":"1978","journal-title":"West J Med"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0014","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0002-9343(98)00362-3","article-title":"Adverse effects of outpatient parenteral antibiotic therapy","volume":"106","author":"Hoffman-Terry","year":"1999","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0015","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0140-6736(03)15266-X","article-title":"Infective endocarditis","volume":"363","author":"Moreillon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0017","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety","author":"Rappo","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0018","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diagmicrobio.2018.10.007","article-title":"Dalbavancin for the management of Gram-positive osteomyelitis: effectiveness and potential utility","volume":"93","author":"Almangour","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0019","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ijantimicag.2018.11.023","article-title":"Treatment of chronic osteomyelitis with multidose oritavancin: a case series and literature review","volume":"53","author":"Chastain","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"10.1016\/j.ijantimicag.2020.106069_bib0020","first-page":"532","article-title":"Dalbavancin for treating prosthetic joint infections caused by Gram-positive bacteria: a proposal for a low dose strategy","volume":"32","author":"Buzon Martin","year":"2019","journal-title":"A retrospective cohort study. Rev Esp Quimioter"},{"issue":"5","key":"10.1016\/j.ijantimicag.2020.106069_bib0021","doi-asserted-by":"crossref","first-page":"e02280","DOI":"10.1128\/AAC.02280-18","article-title":"Safety and efficacy of prolonged use of dalbavancin in bone and joint infections","volume":"63","author":"Morata","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0022","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijid.2019.02.013","article-title":"Multicenter clinical experience of real life dalbavancin use in Gram-positive infections","volume":"81","author":"Wunsch","year":"2019","journal-title":"Int J Infect Dis"},{"issue":"5","key":"10.1016\/j.ijantimicag.2020.106069_bib0023","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ijantimicag.2019.08.006","article-title":"French national cohort of first use of dalbavancin: a high proportion of off-label use","volume":"54","author":"Dinh","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0024","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s15010-019-01354-x","article-title":"Real-world experience with dalbavancin therapy in Gram-positive skin and soft tissue infection, bone and joint infection","volume":"47","author":"Tobudic","year":"2019","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0025","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","article-title":"Dalbavancin in the treatment of different Gram-positive infections: a real-life experience","volume":"51","author":"Bouza","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0026","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1093\/jac\/dkz162","article-title":"On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections","volume":"74","author":"Morrisette","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0027","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40121-019-0247-0","article-title":"Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive Gram-positive infections","volume":"8","author":"Bork","year":"2019","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0028","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz028","article-title":"Dalbavancin as secondary therapy for serious Staphylococcus aureus infections in a vulnerable patient population","volume":"6","author":"Bryson-Cahn","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0029","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/phar.2057","article-title":"Multiple-dose oritavancin evaluation in a retrospective cohort of patients with complicated infections","volume":"38","author":"Schulz","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0030","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40121-017-0156-z","article-title":"Real-world experience with oritavancin therapy in invasive Gram-positive infections","volume":"6","author":"Stewart","year":"2017","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0031","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.12659\/AJCR.905930","article-title":"Multiple weekly dalbavancin dosing for the treatment of native vertebral osteomyelitis caused by methicillin-resistant Staphylococcus aureus: a case report","volume":"18","author":"Almangour","year":"2017","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0032","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/IPC.0000000000000599","article-title":"Successful treatment of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis with outpatient oritavancin therapy","volume":"26","author":"Ruggero","year":"2018","journal-title":"Infect Dis Clin Pract"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0033","first-page":"1","article-title":"Oritavancin for the treatment of daptomycin nonsusceptible vancomycin-resistant Enterococci osteomyelitis","volume":"26","author":"Foster","year":"2017","journal-title":"Infect Dis Clin Pract"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0034","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1002\/phar.1957","article-title":"Successful treatment of methicillin susceptible Staphylococcus aureus osteomyelitis with oritavancin","volume":"37","author":"Delaportas","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0035","doi-asserted-by":"crossref","first-page":"234","DOI":"10.7150\/jbji.37980","article-title":"Dalbavancin to treat infected massive endoprostheses: a case report and cost comparison analysis","volume":"4","author":"Azamgarhi","year":"2019","journal-title":"J Bone Jt Infect"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0036","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.eimc.2017.04.009","article-title":"Dalbavancin treatment of prosthetic knee infection due to oxacillin-resistant Staphylococcus epidermidis","volume":"36","author":"Ramirez Hidalgo","year":"2018","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0037","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/ciy279","article-title":"Dalbavancin as primary and sequential treatment for Gram-positive infective endocarditis: 2-year experience at the general hospital of Vienna","volume":"67","author":"Tobudic","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0038","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12941-019-0329-6","article-title":"Dalbacen cohort: dalbavancin as consolidation therapy in patients with endocarditis and\/or bloodstream infection produced by Gram-positive cocci","volume":"18","author":"Hidalgo-Tenorio","year":"2019","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0039","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41426-018-0205-z","article-title":"Emergence of a dalbavancin induced glycopeptide\/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis","volume":"7","author":"Kussmann","year":"2018","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0040","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/jcpt.12580","article-title":"Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin","volume":"43","author":"Steele","year":"2018","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0041","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofv156","article-title":"Prolonged use of oritavancin for vancomycin-resistant Enterococcus faecium prosthetic valve endocarditis","volume":"2","author":"Johnson","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0042","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz235","article-title":"Left ventricular assist device infections and the potential role for dalbavancin: a case report","volume":"6","author":"Howard-Anderson","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0043","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz427","article-title":"Serum bactericidal activity levels monitor to guide intravenous dalbavancin chronic suppressive therapy of inoperable staphylococcal prosthetic valve endocarditis: a case report","volume":"6","author":"Spaziante","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0044","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1086\/427283","article-title":"Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens","volume":"40","author":"Raad","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0045","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/jcpt.12306","article-title":"Treatment of methicillin-sensitive Staphylococcus aureus bacteremia secondary to septic phlebitis using dalbavancin","volume":"40","author":"Cho","year":"2015","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0046","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijid.2018.07.016","article-title":"Successful treatment of Enterococcus faecalis bacteremia with dalbavancin as an outpatient in an intravenous drug user","volume":"76","author":"Jones","year":"2018","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0047","first-page":"389","article-title":"Treatment with dalbavancin in a patient with septic thrombophlebitis of the internal jugular vein due to Staphylococcus aureus after insertion of an implantable cardioverter defibrillator","volume":"36","author":"Martinez-Sanz","year":"2018","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2017.07.028","article-title":"Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen","volume":"24","author":"Werth","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1016\/j.ijantimicag.2020.106069_bib0049","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s15010-019-01379-2","article-title":"Dalbavancin as a second-line treatment in methicillin-resistant Staphylococcus aureus prosthetic vascular graft infection","volume":"48","author":"Ciccullo","year":"2019","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0050","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jgar.2019.03.015","article-title":"Clinical experience with dalbavancin for the treatment of deep sternal wound infection","volume":"18","author":"Bartoletti","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0051","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13019-017-0690-5","article-title":"Dalbavancin treatment in a deep sternal wound MRSA infection after coronary artery bypass surgery: a case report","volume":"13","author":"Guzek","year":"2018","journal-title":"J Cardiothorac Surg"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0052","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4103\/jpp.JPP_2_17","article-title":"Dalbavancin use for the treatment of methicillin-resistant Staphylococcus aureus pneumonia","volume":"8","author":"Barber","year":"2017","journal-title":"J Pharmacol Pharmacother"},{"issue":"7","key":"10.1016\/j.ijantimicag.2020.106069_bib0053","doi-asserted-by":"crossref","first-page":"e02622","DOI":"10.1128\/AAC.02622-18","article-title":"Treatment of multidrug-resistant vancomycin-resistant Enterococcus faecium hardware-associated vertebral osteomyelitis with oritavancin plus ampicillin","volume":"63","author":"Dahesh","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0054","first-page":"276","article-title":"Dalbavancin treatment of methicillin-susceptible Staphylococcus aureus pyomyositis with torpid evolution: a case report","volume":"32","author":"Alvarez Otero","year":"2019","journal-title":"Rev Esp Quimioter"},{"issue":"2","key":"10.1016\/j.ijantimicag.2020.106069_bib0055","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/0890334419862214","article-title":"Mammary dysbiosis and nipple blebs treated with intravenous daptomycin and dalbavancin","volume":"36","author":"Mitchell","year":"2020","journal-title":"J Hum Lact"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0056","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0193-953X(05)70081-2","article-title":"Medical consequences of substance abuse","volume":"22","author":"Stein","year":"1999","journal-title":"Psychiatr Clin N Am"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0057","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3109\/00952991003592311","article-title":"Risk practices associated with bacterial infections among injection drug users in Denver, Colorado","volume":"36","author":"Phillips","year":"2010","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0058","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0059","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cis803","article-title":"Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America","volume":"56","author":"Osmon","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0060","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa1710926","article-title":"Oral versus intravenous antibiotics for bone and joint infection","volume":"380","author":"Li","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2020.106069_bib0061","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1128\/AAC.01264-06","article-title":"In vivo pharmacodynamic activity of the glycopeptide dalbavancin","volume":"51","author":"Andes","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 3","key":"10.1016\/j.ijantimicag.2020.106069_bib0062","doi-asserted-by":"crossref","first-page":"S203","DOI":"10.1093\/cid\/cir923","article-title":"Oritavancin microbiologic features and activity results from the surveillance program in the United States","volume":"54","author":"Mendes","year":"2012","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920302399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920302399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:39:34Z","timestamp":1760377174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920302399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0924857920302399"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106069","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106069"}}